SLC18A2
Synaptic vesicular amine transporter
As of the edition of 20 October 2026, SLC18A2 (synaptic vesicular amine transporter, UniProt Q05940) has 9 drugs tested at it and 30 companies on the list, 0 on route A and 7 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q05940
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 37
- Disease areas
- Mental health; Nervous system; Inherited and neonatal; Chemically induced; Heart and blood vessels; Nutrition and metabolism; Pregnancy and women's health; Urinary and reproductive
- Registered trials of its drugs
- 180
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 8 |
| Withdrawn from market | 1 |
| Total | 9 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Lisdexamfetamine | Marketed | Phase 4 | none listed |
| Dextroamphetamine | Marketed | Phase 4 | none listed |
| Valbenazine | Marketed | Phase 4 | Ends 2036 |
| Tetrabenazine | Marketed | Phase 4 | none listed |
| Reserpine | Marketed | Phase 3 | none listed |
| Benzphetamine | Marketed | No phase stated | none listed |
| Deserpidine | Marketed | No phase stated | none listed |
| Levamfetamine | Withdrawn from market | No phase stated | none listed |
| Rescinnamine | Marketed | No phase stated | none listed |
9 of 9 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 7 |
| Undetermined | 23 |
| Total on the list | 30 |
| Company | Route |
|---|---|
| Neurocrine | Route B |
| Takeda | Route B |
| Teva | Route B |
The other 27 companies at SLC18A2
In the product30 companies in all; 27 are not named here, and no score is.
See the 30 companies at SLC18A2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.